Targeting the ERBB family in cancer: Couples therapy

Niall Tebbutt, Mikkel W. Pedersen, Terrance G. Johns

Research output: Contribution to journalReview article

196 Citations (Scopus)

Abstract

The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many types of solid tumour. Various therapeutics targeting these receptors have been approved for the treatment of several cancers. Considerable preclinical data have shown that the administration of two inhibitors against an individual ERBB family member-particularly epidermal growth factor receptor (EGFR) or ERBB2-leads to markedly higher antitumour activity than the administration of single agents. This Opinion article describes the preclinical and clinical performance of these dual-targeting approaches, discusses the key mechanisms that mediate their increased efficacy and highlights areas for ongoing investigation.

Original languageEnglish
Pages (from-to)663-673
Number of pages11
JournalNature Reviews : Cancer
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 2013
Externally publishedYes

    Fingerprint

Cite this

Tebbutt, N., Pedersen, M. W., & Johns, T. G. (2013). Targeting the ERBB family in cancer: Couples therapy. Nature Reviews : Cancer, 13(9), 663-673. https://doi.org/10.1038/nrc3559